Glenmede Trust’s DexCom DXCM Stock Holding History

Glenmede Trust’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.9M	Buy	399,521 +4,770	+1%	+$318K	0.12%	145
2026 Q1	$24.8M	Buy	394,751 +105,928	+37%	+$7.38M	0.12%	143
2025 Q4	$19.2M	Buy	+288,823	New	+$18.7M	0.09%	188
2025 Q1	$492K	Buy	7,211 +1,118	+18%	+$91.2K	﹤0.01%	917
2024 Q4	$474K	Buy	+6,093	New	+$451K	﹤0.01%	948
2024 Q3	–	Sell	-5,056	Closed	-$573K	–	1397
2024 Q2	$573K	Buy	5,056 +879	+21%	+$111K	﹤0.01%	857
2024 Q1	$579K	Buy	4,177 +432	+12%	+$54.3K	﹤0.01%	878
2023 Q4	$465K	Sell	3,745 -1,274	-25%	-$130K	﹤0.01%	919
2023 Q3	$468K	Sell	5,019 -119	-2%	-$13.4K	﹤0.01%	862
2023 Q2	$597K	Hold	5,138	–	–	﹤0.01%	786
2023 Q1	$597K	Buy	5,138 +747	+17%	+$83.6K	﹤0.01%	789
2022 Q4	$497K	Buy	4,391 +35	+0.8%	+$3.84K	﹤0.01%	837
2022 Q3	$350K	Buy	+4,356	New	+$369K	﹤0.01%	906
2020 Q4	–	Sell	-632	Closed	-$65K	–	1509
2020 Q3	$65K	Sell	632 -360	-36%	-$37.6K	﹤0.01%	1270
2020 Q2	$99K	Buy	992 +764	+335%	+$68.3K	﹤0.01%	1158
2020 Q1	$12K	Hold	228	–	–	﹤0.01%	2340
2019 Q4	$12K	Sell	228 -492	-68%	-$23.3K	﹤0.01%	2340
2019 Q3	$26K	Buy	720 +336	+88%	+$13.1K	﹤0.01%	1920
2019 Q2	$14K	Hold	384	–	–	﹤0.01%	2220
2019 Q1	$11K	Sell	384 -16	-4%	-$562	﹤0.01%	2319
2018 Q4	$11K	Buy	400 +272	+213%	+$8.63K	﹤0.01%	2225
2018 Q3	$4K	Buy	+128	New	+$3.97K	﹤0.01%	1404
2018 Q2	–	Sell	-356	Closed	-$5K	–	2011
2018 Q1	$5K	Hold	356	–	–	﹤0.01%	2394
2017 Q4	$5K	Sell	356 -148	-29%	-$1.92K	﹤0.01%	2394
2017 Q3	$5K	Sell	504 -60	-11%	-$1.06K	﹤0.01%	2344
2017 Q2	$11K	Hold	564	–	–	﹤0.01%	2089
2017 Q1	$11K	Sell	564 -228	-29%	-$4.45K	﹤0.01%	2089
2016 Q4	$10K	Hold	792	–	–	﹤0.01%	2108
2016 Q3	$17K	Hold	792	–	–	﹤0.01%	1981
2016 Q2	$15K	Buy	792 +412	+108%	+$7.01K	﹤0.01%	1984
2016 Q1	$6K	Sell	380 -92	-19%	-$1.54K	﹤0.01%	2166
2015 Q4	$8K	Hold	472	–	–	﹤0.01%	2132
2015 Q3	$9K	Sell	472 -1,020	-68%	-$22.8K	﹤0.01%	2143
2015 Q2	$28K	Sell	1,492 -200	-12%	-$3.51K	﹤0.01%	1799
2015 Q1	$25K	Sell	1,692 -1,228	-42%	-$18.6K	﹤0.01%	1878
2014 Q4	$39K	Buy	2,920 +1,020	+54%	+$12.5K	﹤0.01%	1825
2014 Q3	$17K	Buy	1,900 +280	+17%	+$2.86K	﹤0.01%	1986
2014 Q2	$15K	Buy	1,620 +1,220	+305%	+$10.8K	﹤0.01%	1929
2014 Q1	$4K	Hold	400	–	–	﹤0.01%	2187
2013 Q4	$3K	Hold	400	–	–	﹤0.01%	2186
2013 Q3	$2K	Hold	400	–	–	﹤0.01%	2133
2013 Q2	$2K	Buy	+400	New	+$1.92K	﹤0.01%	2092

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Glenmede Trust's DXCM Position: Q2 2026 in Review

Glenmede Trust increased its DexCom (DXCM) stake by 1.2% in Q2 2026, buying an estimated $318K and bringing the position to 399,521 shares worth $26.9M. The position accounts for 0.12% of the portfolio, ranked #145.

Glenmede Trust first reported a position in DXCM in Q2 2013 and has held it in 42 quarters since. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Glenmede Trust held 399,521 shares of DexCom worth $26.9M as of Q2 2026.
Glenmede Trust bought 4,770 DexCom shares in Q2 2026, an estimated $318K.
DexCom made up 0.12% of Glenmede Trust's portfolio in Q2 2026, its #145 holding.
Glenmede Trust first reported a position in DexCom in Q2 2013 and has held it in 42 quarters since.
968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.